H7 Investment Fellowship

2025 2nd Cohort Application

H7 VENTURE INVESTMENT

H7 focuses on life-science venture investments, primarily targeting therapeutic companies in IND-enabling or clinical development, and medtech companies that are post-revenue or supported by clinical validation.

H7 is differentiated by its investment approach: we invest based on licensing and M&A demand from multinational pharmaceutical companies—investing with insight from the buy side. This philosophy aligns capital deployment with the real needs and commercialization priorities of global strategic partners.

Submit Deck

INVESTMENT FOCUS

Therapeutics

IND-enabling or clinical-stage stages
Strong potential for near-term licensing or partnership opportunities with global pharmaceutical companies
Strong mechanistic rational and transitional evidence.

Medtech & Diagnostics

Post-revenue solutions or products supported by robust clinical validation
Clear value proposition for clinicians, patients, and payors
Evidence-based adoption and differentiation in competitive markets

Starts from the demand side: Investments are driven by the licensing and M&A priorities of multinational pharmaceutical and medtech companies.

Thinks in eventual transactions: From the outset, we consider how an asset or product could fit into a near-term licensing, co-development, or acquisition scenario.

INVESTMENT PHILOSOPHY

INVESTMENT CRITERIAL

Scientific & Clinical Rigor

Differentiated biology or mechanism
Robust preclinical or clinical evidence
Clear hypotheses and measurable milestones

Strategic Fit With Buyers

Alignment with current and emerging therapeutic or product priorities
Clear potential to fill portfolio gaps at leading pharmaceutical or medtech Corporates

Market & Access Potential

Compelling clinical value proposition
Attractive market dynamics and competitive differentiation
Realistic reimbursement or adoption potential

Execution & Team Excellence

Strong scientific and operational leadership
Credible development plan and milestone strategy
Transparency, integrity, and openness to strategic guidance

Investing with the Insight from the Buy Side.

Invests based on licensing and M&A demand from multinational pharmaceutical companies—an approach that aligns capital deployment with the real commercialization priorities of global strategic partners.